4od1: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Crystal structure of human Fab CAP256-VRC26.03, a potent V1V2-directed HIV-1 neutralizing antibody==
==Crystal structure of human Fab CAP256-VRC26.03, a potent V1V2-directed HIV-1 neutralizing antibody==
<StructureSection load='4od1' size='340' side='right' caption='[[4od1]], [[Resolution|resolution]] 2.69&Aring;' scene=''>
<StructureSection load='4od1' size='340' side='right'caption='[[4od1]], [[Resolution|resolution]] 2.69&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[4od1]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OD1 OCA]. <br>
<table><tr><td colspan='2'>[[4od1]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OD1 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OD1 FirstGlance]. <br>
</td></tr><tr><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.69&#8491;</td></tr>
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ocr|4ocr]], [[4ocs|4ocs]], [[4ocw|4ocw]], [[4od3|4od3]], [[4odh|4odh]], [[4org|4org]]</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4od1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4od1 OCA], [https://pdbe.org/4od1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4od1 RCSB], [https://www.ebi.ac.uk/pdbsum/4od1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4od1 ProSAT]</span></td></tr>
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4od1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4od1 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4od1 RCSB], [http://www.ebi.ac.uk/pdbsum/4od1 PDBsum]</span></td></tr>
</table>
<table>
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 14: Line 14:
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.,Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR Nature. 2014 Mar 2. doi: 10.1038/nature13036. PMID:24590074<ref>PMID:24590074</ref>
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.,Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR Nature. 2014 Mar 2. doi: 10.1038/nature13036. PMID:24590074<ref>PMID:24590074</ref>


From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
</div>
<div class="pdbe-citations 4od1" style="background-color:#fffaf0;"></div>
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Homo sapiens]]
[[Category: Doria-Rose, N A.]]
[[Category: Large Structures]]
[[Category: Gorman, J.]]
[[Category: Doria-Rose NA]]
[[Category: Kwong, P D.]]
[[Category: Gorman J]]
[[Category: Mascola, J R.]]
[[Category: Kwong PD]]
[[Category: Moore, P L.]]
[[Category: Mascola JR]]
[[Category: Morris, L.]]
[[Category: Moore PL]]
[[Category: Schramm, C A.]]
[[Category: Morris L]]
[[Category: Shapiro, L.]]
[[Category: Schramm CA]]
[[Category: Cap256]]
[[Category: Shapiro L]]
[[Category: Fab]]
[[Category: Hiv-1]]
[[Category: Immune system]]
[[Category: V1v2]]
[[Category: Vrc26]]
Retrieved from "https://proteopedia.org/4od1"